Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They currently have a $25.00 target price on the stock.

Several other research firms also recently weighed in on HUMA. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Humacyte in a research report on Monday, December 1st. UBS Group reaffirmed a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. BTIG Research restated a “buy” rating and issued a $6.00 target price on shares of Humacyte in a report on Monday, February 9th. Finally, Benchmark dropped their price target on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 21st. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Humacyte presently has an average rating of “Moderate Buy” and a consensus target price of $8.14.

Humacyte Trading Down 5.3%

Shares of HUMA opened at $1.08 on Thursday. Humacyte has a fifty-two week low of $0.88 and a fifty-two week high of $3.94. The company has a market capitalization of $202.25 million, a PE ratio of -4.70 and a beta of 1.93. The stock has a fifty day moving average of $1.07 and a two-hundred day moving average of $1.41. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62.

Hedge Funds Weigh In On Humacyte

A number of hedge funds have recently made changes to their positions in HUMA. XTX Topco Ltd boosted its holdings in Humacyte by 236.1% in the fourth quarter. XTX Topco Ltd now owns 650,858 shares of the company’s stock valued at $625,000 after purchasing an additional 457,236 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of Humacyte in the 4th quarter valued at approximately $201,000. Millennium Management LLC boosted its stake in shares of Humacyte by 129.5% during the 4th quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock valued at $2,528,000 after buying an additional 1,485,152 shares during the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Humacyte during the fourth quarter worth approximately $82,000. Finally, Bridgeway Capital Management LLC increased its stake in shares of Humacyte by 20.0% in the fourth quarter. Bridgeway Capital Management LLC now owns 210,000 shares of the company’s stock worth $202,000 after buying an additional 35,000 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.